Back to Search
JOSUE CORTES, MD
MD
Pediatrics Physician
NPI: 1790780104Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
ME90573(FL)
Research & Publications (20)
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
PMID 19508387·J Cell Mol Med·2010
7-preclinical
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
PMID 19224852·J Clin Oncol·2009
8-other
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
PMID 19090005·Cancer·2009
8-other
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
PMID 19131547·Blood·2009
8-other
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
PMID 19195046·Cancer·2009
6-review
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
PMID 18703706·Blood·2009
8-other
Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.
PMID 18978822·Bone Marrow Transplant·2009
5-case
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
PMID 19060245·Blood·2009
3-trial
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
PMID 19075265·J Clin Oncol·2009
8-other
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
PMID 19118059·Clin Cancer Res·2009
3-trial
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
PMID 19118067·Clin Cancer Res·2009
8-other
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
PMID 19181650·Mayo Clin Proc·2009
6-review
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
PMID 19193436·Leuk Res·2009
3-trial
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
PMID 19013640·Leuk Res·2009
8-other
Reproductive medicine meets human embryonic stem cell (hESC) research: the need to adjust the regulatory framework to actual expectations and potential detrimental consequences of hESC research.
PMID 18692797·Fertil Steril·2009
8-other
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
PMID 18715642·Leuk Res·2009
8-other
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
PMID 19029442·Blood·2009
3-trial
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
PMID 19117345·Cancer·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1651 N SEMORAN BLVD
ORLANDO, FL 32807 - Phone
- (407) 249-1234
Quick Facts
- NPI
- 1790780104
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile